The Forgotten Hepatitis B Donor in Heart Transplantation

In the past, Hepatitis B donors have been declined in patients who have not been vaccinated by the Hepatitis B vaccine. There is concern that these donors would transmit Hepatitis B to the recipient if they are not vaccinated. There is treatment available for these Hepatitis B infections, however, it has not been established as to its efficacy in patients on immunosuppression. In addition, hepatitis viruses have been reported to affect the endothelium of vital organs. Hepatitis B may injure the endothelium of the coronary vascular tree and could potentially result in a greater development of cardiac allograft vasculopathy (CAV) after heart transplantation.
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: Tags: (1224) Source Type: research

Related Links:

Hepatitis B virus (HBV) is a virus species belonging to Hepadnaviridae family which is partial double-stranded DNA viruses (Pourkarim et al., 2014). This virus affects nearly 2 billion people around the world (Wang et al., 2019) and it has been reported as one of the two major causing and risk factors (the second is Hepatitis C Virus) for hepatocellular carcinoma (HCC) in the Sudan (Abou et al., 2009). Several studies have characterized HBV as extremely endemic in Sudan as the hepatitis B surface antigen HBsAg was reported to have a prevalence of approximately 16%-20% in the Sudanese population rate (Elduma and Saeed, 2011).
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
esse Elizabeth Vincan An emerging theme for Wnt-addicted cancers is that the pathway is regulated at multiple steps via various mechanisms. Infection with hepatitis B virus (HBV) is a major risk factor for liver cancer, as is deregulated Wnt signaling, however, the interaction between these two causes is poorly understood. To investigate this interaction, we screened the effect of the various HBV proteins for their effect on Wnt/β-catenin signaling and identified the pre-core protein p22 as a novel and potent activator of TCF/β-catenin transcription. The effect of p22 on TCF/β-catenin trans...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
co Giannini Hepatocellular carcinoma (HCC), the most frequent primary liver cancer, is the sixth most common cancer, the fourth leading cause of cancer-related deaths worldwide, and accounts globally for about 800,000 deaths/year. Early detection of HCC is of pivotal importance as it is associated with improved survival and the ability to apply curative treatments. Chronic liver diseases, and in particular cirrhosis, are the main risk factors for HCC, but the etiology of liver disease is rapidly changing due to improvements in the prevention and treatment of HBV (Hepatitis B virus) and HCV (Hepatitis C virus) infect...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
HBV-specific CD8 T cells present higher TNFα expression but lower cytotoxicity in hepatocellular carcinoma. Clin Exp Immunol. 2020 May 31;: Authors: Zhao L, Jin Y, Yang C, Li C Abstract TNFα is largely regarded as a proinflammatory cytokine, but several recent researches demonstrated that TNFα could possess immunoregulatory roles with potential to suppress antitumor immunity. Chronic hepatitis B virus (HBV) infection is a major risk factor of hepatocellular carcinoma (HCC) and HBV-specific CD8 T cells could exert antitumor roles in HCC patients. Here, we found that HBV-specific CD8 T...
Source: Clinical and Developmental Immunology - Category: Allergy & Immunology Authors: Tags: Clin Exp Immunol Source Type: research
This study aimed to evaluate the effects of LLV on HCC development, mortality, and cirrhotic complications among patients according to their adherence to entecavir (ETV) treatment. Methods: We performed a retrospective observational analysis of data from 894 consecutive adult patients with treatment-naïve CHB undergoing ETV treatment. LLV was defined according to either persistent or intermittent episodes of
Source: Clinical and molecular hepatology - Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research
Authors: Woo HY, Park JY, Bae SH, Kim CW, Jang JY, Tak WY, Kim DJ, Kim IH, Heo J, Ahn SH Abstract Background/Aims: Suboptimal responses to lamivudine or telbivudine plus adefovir (LAM/LdT+ADV) rescue therapy are common in patients with LAM-resistant hepatitis B virus (HBV) infections. We compared patients switched to entecavir plus tenofovir (ETV+TDF) to those maintained on LAM/LdT+ADV. Methods: This prospective randomized controlled trial examined 91 patients whose serum HBV DNA levels were greater than 60 IU/mL after at least 24 weeks of treatment with LAM/LdT+ADV for LAM-resistant HBV. Patients were randomiz...
Source: Clinical and molecular hepatology - Category: Gastroenterology Tags: Clin Mol Hepatol Source Type: research
Publication date: Available online 25 May 2020Source: The Brazilian Journal of Infectious DiseasesAuthor(s): Ludy Vargas, Fernanda Bastos, André Guimarães, Sávio Amaral, Tarcisio Fausto, Maria Arriaga, Manoel Sarno, Carlos Brites
Source: The Brazilian Journal of Infectious Diseases - Category: Infectious Diseases Source Type: research
CONCLUSION: MiR-98-5p inhibits the secretion of HBV, proliferation, migration, and invasion of HBV-HCC cells by targeting NIK. PMID: 32469170 [PubMed - in process]
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
Abstract BACKGROUND: Survival after liver resection of hepatocellular carcinoma (HCC) remains poor because of a high incidence of recurrence. We sought to investigate risk factors, patterns, and long-term prognosis among patients with early and late recurrence after liver resection for hepatitis B virus (HBV)-associated HCC. METHODS: Data of consecutive patients undergoing curative resection for HBV-associated HCC were analyzed. According to the time to recurrence after surgery, recurrence was divided into early (≤2 years) and late recurrence (>2 years). Characteristics, patterns of initia...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
Authors: Mak LY, Ko KL, To WP, Wong DK, Seto WK, Fung J, Yuen MF Abstract Serum hepatitis B core-related antigen (HBcrAg) was shown to predict the risk of hepatocellular carcinoma (HCC) in chronic hepatitis B (CHB) patients undergoing treatment. We investigated the longitudinal profile of HBcrAg in entecavir (ETV)-treated CHB patients with subsequent HCC development. We identified HCC cases diagnosed at ≥1 year after ETV initiation. CHB patients without HCC (matched for age, sex, cirrhosis status, baseline hepatitis B virus (HBV) DNA level, and ETV treatment duration) were identified as controls at an HCC:non-HC...
Source: Gut and Liver - Category: Gastroenterology Tags: Gut Liver Source Type: research
More News: Bone Graft | Cardiology | Heart | Heart Transplant | Hepatitis | Hepatitis B | Hepatitis Vaccine | Lung Transplant | Transplant Surgery | Transplants | Vaccines